Navigation Links
Champions Oncology Reports Full Year 2011 Financial Results
Date:7/15/2011

r POS were 53% and 65%, respectively.  The decrease in gross margin was attributable to the reduction in POS prices that the Company has instituted to increase affordability and market potential of the services being offered.

Costs of TOS for the fiscal year 2011 and 2010 were $1.5 million and $0.8 million, respectively, an increase of $0.7 million, or 93%.  For the fiscal year 2011 and 2010, gross margins for TOS was 56% and 53%, respectively.  

Research and DevelopmentResearch and development, or R&D, expenses for fiscal year 2011 and 2010 were $3.0 million and $2.6 million, respectively, an increase of $0.4 million, or 12%.  The increase in R&D expenses in 2011 was primarily due to the Company's increased spending on its technology platform and Tumorgraft testing on the company's in-licensed compounds.

General and AdministrativeGeneral and administrative, or G&A, expenses for the fiscal year 2011 and 2010 were $4.6 million and $2.8 million, respectively, an increase of $1.8 million, or 67%.  The increase was primarily due to the $2.3 million of non-cash stock-based compensation expense related to stock options issued to the Company's Chief Executive Officer and President.

Sales and MarketingSales and marketing expenses for the fiscal year 2011 and 2010 were $1.4 million and $0.5 million, respectively, and increase of $0.9 million or 173%.  The increase was primarily due to the hiring of additional sales employees and $0.3 million in new marketing efforts.

Other Income (Expense), NetOther income (expense), net for the fiscal year 2011 was $1.5 million, which primarily relates to grant income earned under the Qualifying Therapeutic Discovery Project program administered under Section 48D of the Internal Revenue Code based on the qualifying expenses incurred through the fiscal year ended April 30, 2011.

Cash and Cash EquivalentsThe Company's cash position on April 30,
'/>"/>

SOURCE Champions Oncology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Champions Oncology (formerly Champions Biotechnology) Completes $9.4 Million Financing
2. Champions Biotechnology Changes Name to Champions Oncology
3. Champions Announces Technology Collaboration Utilizing Champions Tumorgraft™ Technology Platform for Oncology Drug Development
4. Champions Biotechnology Reports Fiscal 2011 Third Quarter Financial Results
5. Champions Biotechnology Reports Additions to its Management Team
6. Champions Biotechnology Reports Fiscal 2011 First Quarter Financial Results
7. Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
8. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
9. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
10. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
11. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... The North American crystal oscillator market report defines and ... forecast of revenue. This market was valued at $531.4 ... million by 2018, at a CAGR of 3.3% from ... the North American crystal oscillator market report, to get ... provides a glimpse of the segmentation of the market, ...
(Date:10/22/2014)... Cranford, NJ (PRWEB) October 22, 2014 ... technologies and services – has been working with a ... Health and New Haven Farms Community Farming Collaborative to ... iPad-based ePRO solution. The study, which started in ... Wellness program that provides participants weekly exposure to and ...
(Date:10/22/2014)... 2014 Physicians Choice Laboratory Services ... menu, which enables healthcare providers to individualize therapeutic ... evidence-based results, healthcare providers are better able to ... while minimizing risks for adverse drug reactions and ... the FDA [1] more than 2.2 million adverse ...
(Date:10/22/2014)... /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... its Oral Amphotericin B program.  The company recently ... work involving samples from HIV/AIDS patients exposed ... pre clinical studies and regulatory filings to move ... utilizing approximately $700,000 of funding and technological advice ...
Breaking Biology Technology:The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 2The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 3The North American crystal oscillator market is expected to reach $623.6 million by 2018 - New Report by MicroMarket Monitor 4myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3
... Implementation of a controversial web-based software system to manage ... proceed, a report on an in-depth assessment of the ... suggests that the UW System continue to work with ... the Appointments, Payroll and Benefits System (ABPS) project, which ...
... - Trying to find a vaccine for AIDS is tricky ... places on a sprawling university campus, it's downright daunting. , ... Laboratory opened on Sept. 16, the prospects for eventual success ... on a technique that may hold greater promise to prevent ...
... Wisconsin companies that won more than a combined $42 ... Business Technology Transfer (STTR) awards over the last two ... Madison. , ,The awards banquet will be preceded by ... focus on SBIR/STTR funding opportunities. The keynote speaker at ...
Cached Biology Technology:Report gives nod to controversial Lawson project 2Report gives nod to controversial Lawson project 3Report gives nod to controversial Lawson project 4New digs for UW AIDS researchers 2
(Date:10/15/2014)... risk from strains of influenza virus increases with the ... become complacent that the most substantial threats have been ... pandemics arise when a new virus strain – against ... spreads in the human population. There have been five ... of which – the 1918 Spanish Flu – cost ...
(Date:10/15/2014)... 15, 2014 NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market releases photos and video of ... on Monday October 13 th . Gino ... and angel investor Mr. Chad A. Verdi rang ... NXT-ID thanked his investors and employees "for their work and dedication ...
(Date:10/14/2014)... 2014)—It,s been millions of years since T. rex ... by Ohio University scientists is breathing life back into ... dinosaur snouts. The research has important implications for how ... to enhance the sense of smell and cool their ... Ohio University doctoral student Jason Bourke, lead author of ...
Breaking Biology News(10 mins):Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3
... UK scientist has discovered clumps of previously-unreported callus hairs ... and closely-related varieties, which may have storage implications for ... apples is really exciting, says Dr Mary Parker of ... for about as long as human history and Fuji ...
... DALLAS March 25, 2008 Researchers at ... $6.5 million grant from the National Institute of ... anti-microbial compound to target bacterial pathogens such as ... drugs are available in the marketplace, new ones ...
... humans, are true farmers. The difference is that ants ... Sen Brady at the Smithsonians National Museum of Natural ... issue of the journal Proceedings of the National Academy ... of ants and how these abilities have evolved throughout ...
Cached Biology News:Popular apple variety harbors unusual cell growth 2NIH awards $6.5 million grant to UT Southwestern to develop new antibiotic 2Smithsonian's National Museum of Natural History reveals ants as fungus farmers 2
Request Info...
PGC-1 (H-300)...
Mouse VEGF R1/Flt-1 Allophycocyanin MAb (Clone 141522) Keywords: Receptor Tyrosine Kinase, RTK, VEGFR1, VEGF Receptor 1 Protein Family: Receptor Tyrosine Kinases, VEGF/PDGF Family...
Mouse Anti-Amyloid beta [1-16], clone 6E10, Monoclonal Antibody...
Biology Products: